the Challenge

Dr. Bruce Patterson

FOUNDER AND
CHIEF EXECUTIVE OFFICER

Bruce K. Patterson, M.D. is a leading researcher on the effects of viral pathogens on the human immune system. His pioneering technologies and findings have contributed to advances in detection, prognosis and treatment of patients infected with HIV, HPV, cervical cancer, COVID-19 and other diseases.

As Founder and Chief Executive Officer of HealthBioAI, Dr. Patterson developed a new paradigm for predicting, identifying and treating long COVID-19 and other viral pathogens that impair the immune system’s ability to function effectively, as well as a patented treatment protocol for long Covid, currently within the application process with the FDA.

Dr. Patterson received his undergraduate degree in microbiology from the University of Michigan and his M.D. from Northwestern University, where he later served as Chief Resident of Pathology at Northwestern Memorial Hospital. He has authored more than 150 manuscripts and book chapters.

Chris Wheeler

CHIEF FINANCIAL OFFICER

Chris Wheeler is the CFO of HealthBioAI, who brings a wealth of experience in forming, funding and growing healthcare companies.  He is named inventor on many core technologies in the healthcare diagnostics space.  He has a Science, Math, Engineering, and Business background and is a results-driven executive who has worked in Silicon Valley for over 20 years. 

Chris has founded and owned a large hospital in the Silicon Valley with revenues exceeding $100M per year. He has a proven track record of building successful businesses, managing P&Ls, growing revenue, and sourcing capital. Chris has led projects and programs related to toxicology, large scale health data, cardiac surgery, catheter manufacturing, drug delivery, cancer diagnostics, and several other areas within the healthcare industry.

Chris has success in moving-the-needle on operational improvements at Baxter’s Cardiovascular Group’s manufacturing plant in Puerto Rico. He implemented a financial and commercialization strategy for a breath-based diagnostics company out of Stanford University. Chris has demonstrated success  in leading companies from inception to product-market fit, to rapid revenue growth, and broad market expansion.  Chris has over 15 years of experience on Boards and has an excellent understanding of corporate governance.  Chris has founded or formed multiple companies that achieved breakthrough performance in their respective sectors.

Brian Brothen

CHIEF COMMERCIAL OFFICER

Throughout his career, Brian Brothen has a proven track record of strategic, result-driven, innovative business development in the pharmaceutical, diagnostic and biotech industries. He possesses a keen business acumen and excellent communication, leadership, and problem-solving skills within the C-suite environment.

Brian leverages his 20+ years of successful experience in executive commercial leadership positions.  His track record includes launching and leading biotech sales and business development teams, establishing national physician advisory boards, exceeding financial goals while building strong relationships with key stakeholders. 

Dan Casey

SR. VICE PRESIDENT,
STRATEGIC DEVELOPMENT

Dan Casey has joined HealthBioAI as Senior Vice President,  Strategic Development.  He brings a 25+ year background in building, launching, and leading commercial teams across companies of all sizes, including Sanofi, Emergent BioSolutions, and Galderma Labs. 

Dan brings expertise in strategic and operational planning, using his deep insights to shape customer and patient engagement models, meticulously plan product launches, navigate change and communicate effectively with all audiences.

What truly sets Dan apart is his passion for making a real impact in the world of healthcare and his unwavering commitment to both patients and business growth. Throughout his career, Dan has consistently balanced prioritizing patient care while exceeding financial objectives in each of his commercial roles.  As part of the management team, Dan is establishing a sense of accountability, teamwork and revenue growth within the culture of the company.

Stefan Glück, MD, PhD

SR. VICE PRESIDENT, MEDICAL AFFAIRS

Stefan Glück, M.D., PhD, is a medical oncologist specializing in breast, ovarian, and bladder cancers, as well as immunology and hematology. He has led early-stage development studies of solid tumors and immuno-oncology. He has deep expertise in clinical trials, acting as the PI in several dozen. 

Dr. Glück has authored/co-authored more than 250 articles, presented more than 350 papers at national and international meetings, and written/co-written multiple book chapters. He is a reviewer of several journals, including the Journal of Clinical Oncology, European Journal of Cancer, Lancet Oncology, Lancet, Breast Cancer Research, The Oncologist, The Breast Journal, and Clinical Breast Cancer.

Dr. Glück was presented the America’s Top Oncologists 2008 award from Consumers’ Research Council of America; he also received the Best Doctors in America honor in since 2006, and has annually earned that prestige every year, including in 2014; this award was warranted after less than 3 years of working in the United States.